Skip to main content
Category

Research

ResearchTreatments

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

*November 2021* The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising the necessity for further biomarker assessment. In this work, by…
laurabbook@gmail.com
December 8, 2021
ResearchTreatments

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

*October 2021* Highlights Acquired resistance mechanisms to osimertinib can be EGFR dependent or independent. First- and fourth-generation EGFR-TKIs are able to overcome EGFR-dependent resistance. MET and MEK inhibitors may overcome EGFR-independent resistance. Anti-HER/MET novel monoclonal antibody seems effective across multiple resistance mechanisms. Carboplatin/paclitaxel ± bevacizumab/atezolizumab represents a feasible option in…
laurabbook@gmail.com
December 8, 2021
ResearchTreatments

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation

*October 2021* Purpose: This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. Methods: We identified patients with stage IV EGFR-mutant non-oligometastatic NSCLC who were suitable to receive SBRT for the primary tumors after EGFR-TKI treatment. All…
laurabbook@gmail.com
November 12, 2021